🇺🇸 FDA
Pipeline program

rolistobart, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL , CARBOPLATIN , MK-4830, MK-4830, PEMETREXED , boserolimab, vibostolimab

MK-3475-01A

Phase 2 small_molecule active

Quick answer

rolistobart, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL , CARBOPLATIN , MK-4830, MK-4830, PEMETREXED , boserolimab, vibostolimab for non-small cell lung cancer is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
non-small cell lung cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials